Sonic Healthcare Ltd (ASX: SHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Sonic Healthcare Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $11.50 billion
P/E Ratio 21.79
Dividend Yield 4.60%
Shares Outstanding 494.24 million
Earnings per share 1.067
Dividend per share 1.07
Year To Date Return 2.83%
Earnings Yield 4.59%
Franking 35
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Sonic Healthcare Ltd (ASX: SHL)
    Latest News

    asx buy
    ⏸️ ASX Shares

    2 compelling ASX 200 blue chip shares to buy in April

    Cochlear Limited (ASX:COH) and this compelling ASX blue chip share could be the ones to buy in April. Here's why...

    Read more »

    A man walks up three brick pillars to a dollar sign.
    Dividend Investing

    2 high quality ASX dividend shares that smash term deposits

    Australia and New Zealand Banking GrpLtd (ASX:ANZ) and this ASX dividend share could help you beat low interest rates...

    Read more »

    A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies
    Defensive Shares

    2 high-growth ASX COVID-19 shares

    These 2 ASX COVID-19 shares are displaying high levels of growth and could be worth a spot inside your portfolio.

    Read more »

    credit corp share price represented by red alarm clock against bright orange background
    Blue Chip Shares

    2 ASX 200 shares to buy for growth

    The two S&P/ASX 200 Index (ASX:XJO) shares here could be good options for growth, including Sonic Healthcare Ltd (ASX:SHL).

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Dividend Investing

    Should income investors buy Sonic Healthcare (ASX:SHL) shares?

    Could Sonic Healthcare Limited (ASX:SHL) shares be great options for income investors in search of dividends?

    Read more »

    A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Defensive Shares

    Why the Sonic (ASX:SHL) share price could be a hidden opportunity

    The Sonic Healthcare Ltd (ASX:SHL) share price could be a hidden opportunity for investors with its high level of COVID-19…

    Read more »

    A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
    ⏸️ ASX Shares

    2 top quality blue chip ASX shares to buy in April

    Goodman Group (ASX:GMG) and this ASX blue chip share could be top options for investors in April. Here's why...

    Read more »

    fingers walking up piles of coins towards bag of cash signifying asx dividend shares
    Dividend Investing

    2 quick-growing ASX dividend shares to buy

    Kogan.com Ltd (ASX:KGN) and this ASX dividend share are growing fast. Here's why they could be great options for income investors...

    Read more »

    covid asx share price represented by man in face mask giving thumbs up
    Growth Shares

    2 COVID-19 ASX shares to buy

    There are some ASX shares that are seeing strong growth during this COVID-19 period, including Sonic Healthcare Ltd (ASX:SHL).

    Read more »

    IAG share price broker upgrade buy
    Broker Notes

    Top brokers name 3 ASX shares to buy today

    Top brokers have named Sonic Healthcare Limited (ASX:SHL) and these ASX shares as buys. Here's why they are bullish on…

    Read more »

    A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
    Share Market News

    4 ASX shares with director buys this month

    Director buys can be a sign that those most in the know view the shares as undervalued. Here are 4…

    Read more »

    Biden stimulus effect on bluescope share price represented by us dollars being printed
    Share Market News

    BlueScope (ASX: BSL) share price could get cut of Biden's US$3tn boost

    The BlueScope Steel Limited (ASX: BSL) share price could get a boost later this week thanks to US President Joe…

    Read more »

    Frequently Asked Questions

    Sonic Healthcare historically makes two partially or fully franked dividend payments to shareholders each year.

    Sonic Healthcare generally pays its shareholder dividends in March and September.

    Yes, Sonic Healthcare offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on its ordinary shares.

    Sonic Healthcare Ltd listed on the ASX on 30 April 1987.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    03 Sep 2025 $0.6300 35.00% Final 18 Sep 2025
    05 Mar 2025 $0.4400 0.00% Interim 20 Mar 2025
    04 Sep 2024 $0.6300 0.00% Final 19 Sep 2024
    01 Mar 2024 $0.4300 0.00% Interim 21 Mar 2024
    06 Sep 2023 $0.6200 100.00% Final 21 Sep 2023
    07 Mar 2023 $0.4200 100.00% Interim 22 Mar 2023
    06 Sep 2022 $0.6000 100.00% Final 21 Sep 2022
    08 Mar 2022 $0.4000 100.00% Interim 23 Mar 2022
    07 Sep 2021 $0.5500 65.00% Final 22 Sep 2021
    09 Mar 2021 $0.3600 30.00% Interim 24 Mar 2021
    07 Sep 2020 $0.5100 30.00% Final 22 Sep 2020
    10 Mar 2020 $0.3400 30.00% Interim 25 Mar 2020
    10 Sep 2019 $0.5100 30.00% Final 25 Sep 2019
    08 Mar 2019 $0.3300 20.00% Interim 26 Mar 2019
    12 Sep 2018 $0.4900 30.00% Final 27 Sep 2018
    06 Mar 2018 $0.3200 20.00% Interim 10 Apr 2018
    08 Sep 2017 $0.0000 0.00% Final 11 Oct 2017
    07 Mar 2017 $0.3100 20.00% Interim 11 Apr 2017
    08 Sep 2016 $0.4400 30.00% Final 27 Sep 2016
    03 Mar 2016 $0.3000 30.00% Interim 06 Apr 2016
    05 Sep 2014 $0.4000 55.00% Final 23 Sep 2014
    03 Sep 2012 $0.2923 53.88% Final 09 Oct 2012
    04 Mar 2011 $0.1881 35.62% Interim 24 Mar 2011
    08 Sep 2010 $0.2818 43.47% Final 28 Sep 2010
    03 Mar 2010 $0.1932 43.48% Interim 25 Mar 2010
    08 Sep 2009 $0.2818 43.47% Final 28 Sep 2009
    05 Mar 2009 $0.1936 68.18% Interim 26 Mar 2009
    08 Sep 2008 $0.3200 100.00% Final 09 Oct 2008
    28 Feb 2006 $0.1500 100.00% Interim 20 Mar 2006
    31 Aug 2005 $0.2300 100.00% Final 19 Sep 2005
    26 Feb 2004 $0.1000 100.00% Interim 17 Mar 2004

    SHL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Sonic Healthcare Ltd

    Sonic Healthcare Limited (ASX: SHL) is a global healthcare provider. It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland. It is the second-largest provider in Belgium and New Zealand and the third-largest in the United States.

    While pathology contributes the vast majority of the company's revenue, Sonic Healthcare is also a major provider of diagnostic imaging in Australia and is the largest medical centre operator in the country.

    The company typically earns the majority of its revenue from its European pathology segment, followed by its Australia-New Zealand pathology operations.  

    SHL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Jan 2026 $23.27 $0.20 0.87% 2,724,415 $22.83 $23.30 $22.73
    19 Jan 2026 $23.07 $-0.18 -0.77% 1,199,422 $22.65 $23.07 $22.60
    16 Jan 2026 $23.25 $-0.03 -0.13% 2,058,181 $23.30 $23.32 $22.75
    15 Jan 2026 $23.28 $0.12 0.52% 1,004,699 $23.20 $23.36 $23.09
    14 Jan 2026 $23.16 $0.13 0.56% 1,249,762 $22.94 $23.17 $22.90
    13 Jan 2026 $23.03 $0.20 0.88% 1,496,665 $22.88 $23.22 $22.85
    12 Jan 2026 $22.83 $0.43 1.92% 841,560 $22.45 $22.92 $22.41
    09 Jan 2026 $22.40 $0.07 0.31% 743,099 $22.44 $22.63 $22.35
    08 Jan 2026 $22.33 $0.19 0.86% 761,136 $22.07 $22.41 $22.04
    07 Jan 2026 $22.14 $0.24 1.10% 736,678 $22.00 $22.28 $21.98
    06 Jan 2026 $21.90 $-0.32 -1.44% 1,049,728 $22.24 $22.26 $21.76
    05 Jan 2026 $22.22 $-0.22 -0.98% 602,816 $22.50 $22.60 $22.22
    02 Jan 2026 $22.44 $-0.17 -0.75% 431,186 $22.61 $22.62 $22.41
    31 Dec 2025 $22.61 $0.16 0.71% 868,051 $22.46 $22.61 $22.30
    30 Dec 2025 $22.45 $-0.19 -0.84% 787,164 $22.63 $22.73 $22.36
    29 Dec 2025 $22.64 $0.07 0.31% 544,514 $22.65 $22.68 $22.48
    24 Dec 2025 $22.57 $-0.23 -1.01% 452,233 $22.79 $22.84 $22.51
    23 Dec 2025 $22.80 $0.25 1.11% 887,225 $22.70 $22.85 $22.52

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    20 Nov 2025 Christopher Wilks Issued 34,170 $780,442
    Director remuneration. 1,04,898 Rights
    20 Nov 2025 Christopher Wilks Issued 233,760 $5,339,078
    Director remuneration.
    20 Nov 2025 James Newcombe Issued 345,342 $7,887,611
    Director remuneration.
    20 Nov 2025 James Newcombe Issued 50,481 $1,152,986
    Director remuneration. 50,481 Rights
    18 Nov 2025 Colin Goldschmidt Expiry 321,637 $6,718,996
    Options expired. As per announcement on 21-11-2025
    18 Nov 2025 Christopher Wilks Expiry 122,570 $2,560,487
    Options expired.
    16 Oct 2025 Nicola Wakefield Evans Buy 2,500 $54,450
    On-market trade.
    15 Oct 2025 Katharine Giles Buy 1,000 $21,169
    On-market trade.
    03 Oct 2025 Katharine Giles Buy 1,000 $21,720
    On-market trade.
    02 Oct 2025 Mark Compton Buy 1,500 $32,355
    On-market trade.
    01 Oct 2025 Christine Bennett Buy 1,100 $23,661
    On-market trade.
    26 Sep 2025 Kathryn (Kate) Spargo Buy 3,500 $74,421
    On-market trade.
    26 Sep 2025 Suzanne Crowe Buy 2,365 $49,948
    On-market trade.
    02 Sep 2025 Colin Goldschmidt Exercise 9,852 $233,985
    Conversion of securities. 172,148 - performance rights
    02 Sep 2025 Colin Goldschmidt Buy 9,852 $233,985
    Conversion of securities.
    02 Sep 2025 Christopher Wilks Exercise 3,754 $89,157
    Conversion of securities. 72,240 performance rights
    02 Sep 2025 Christopher Wilks Buy 3,754 $89,157
    Conversion of securities.
    09 Apr 2025 Christine Bennett Buy 1,000 $25,000
    On-market trade.
    08 Apr 2025 Katharine Giles Buy 850 $21,012
    On-market trade. As per announcement on 08/04/2025.
    25 Mar 2025 Nicola Wakefield Evans Buy 2,000 $51,200
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Christopher David Wilks Chief Financial OfficerFinance Director Dec 1989
    Mr Wilks became Finance Director and Chief Financial Officer of Sonic Healthcare in 1993. He was previously a partner in a private investment bank.
    Mr Mark Raymond Compton Non-Executive DirectorNon-Executive Chairman Oct 2014
    Prof Compton has senior executive experience in healthcare services. He is currently Adjunct Professor in Management at Macquarie University, Nonexecutive Director of The Hospitals Contribution Fund of Australia and Nonexecutive Chairman of not for profit organisations St Lukes Care and the Order of St John. He was also Chairman of the Woolcock Institute of Medical Research, Nonexecutive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia. In recognition of his work in the healthcare sector and his service to the community, he was awarded the Centenary Medal of the Commonwealth of Australia, appointed by Her Majesty the Queen as a Knight in the Order of St John in 2004 and as Bailiff Grand Cross in 2017, and was appointed as a Member of the Order of Australia (AM) in January 2010.
    Mr Neville Mitchell Non-Executive Director Sep 2017
    Mr Mitchell has international healthcare and finance experience. He has also performed roles with a number of industry and government committees. He is a member of the Risk Management Committee.
    Professor Suzanne Crowe Non-Executive Director Apr 2020
    Professor Crowe is an Emeritus Professor of Medicine at Monash University, Melbourne. She was a Nonexecutive Director of St Vincents Health Australia Ltd. She retired from Burnet Institute as Associate Director in 2018 following a 30 year research career, having played an integral role in Burnets development as a global research organisation. She retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne. She has served as a Member of the Prime Ministers Science Engineering and Innovation Council, as Head of the World Health Organization (WHO) Regional Reference Laboratory for HIV Resistance Testing and as an HIV advisor to WHO for 25 years. She was appointed a Fellow of the Australian Academy of Health and Medical Sciences in 2015, and an Officer of the Order of Australia (AO) in 2020, in recognition of her distinguished service to health and aged care administration, clinical governance, biomedical research, and to education. She is Chair of the Risk Management Committee.
    Professor Christine Constance Bennett Non-Executive Director Sep 2022
    Professor Bennett has over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. She is an experienced nonexecutive director in forprofit and social enterprises, Patron of Research Australia, Convenor of the Champions of Change Health Coalition STEM and Health Group for gender equality, and a member of Chief Executive Women. She is also an advisor to the Digital Health Cooperative Research Centre and in 2024 completed a certificate on AI Ethics and Board Oversight. Her previous Board nonexecutive director roles include Telstra Health, HeartWare Limited, Symbion Health Limited and Chair of Sydney Childrens Hospital Network. In December 2021, she retired from and was awarded Emeritus Professor by The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships and Dean, School of Medicine, Sydney for over ten years. Her prior experience has included being Group Executive and Chief Medical Officer for MBF and then Bupa Health and Care Services; CEO and later Chair of Research Australia; Managing Director of Total Health Enterprise Ltd; Partner in Health and Life Sciences for KPMG Australia; CEO of Westmead Hospital and Community Health Services; General Manager for the Royal Hospital for Women; and Head of Planning in NSW Health. She has an active commitment to and involvement in medical professional issues, public policy and medical research. In 2008 she was appointed as Chair of the National Health and Hospitals Reform Commission producing a longterm blueprint for reform of health and aged care in Australia. She was awarded an Officer of the Order of Australia (AO) in the 2014 Australia Day Honours in recognition of her distinguished service to medicine and health care leadership. She is a member of the Risk Management Committee.
    Ms Kathryn (Kate) Dianne Spargo Non-Executive Director Jul 2010
    Ms Spargo has gained broad business experience as both a legal advisor, having worked in private practice and government, and as a director. She has been a director of both listed and unlisted companies for more than 20 years. She also holds nonexecutive director roles with CIMIC Group Limited, the Future Fuels Cooperative Research Centre and Geelong Football Club Limited. She was previously a Nonexecutive Director of Fletcher Building Limited, Xenith IP Group Limited, Adairs Limited and Sigma Healthcare Limited.
    Ms Nicola Wakefield Evans Non-Executive Director Feb 2025
    Ms Evans is a highly experienced nonexecutive director and business leader. Over a 35 year international career, she has gained a broad range of commercial, business management, strategy and legal experience in the financial services, health, energy and infrastructure sectors. She was a corporate advisory partner at King & Wood Mallesons for more than 20 years and also held several key management positions at the firm including Managing Partner International in Hong Kong and Managing Partner, Practice in Sydney. She is currently a member of the Australia Future Fund Board of Guardians. She is also Chair of MetLife Australia and a panel member of the Australian Governments Takeovers Panel. In 2019 she was invited by the Australian Government to be a member of the Australian delegation to the United Nations Commission on the Status of Women. She is a member of Chief Executive Women, and in 2023 was appointed as a Member of the Order of Australia (AM) in recognition of significant service to business, the law, and diversity.
    Dr Katharine Giles Non-Executive Director Sep 2022
    Dr Giles is a registered medical practitioner with the Medical Board of Australia. After initially practicing as a medical doctor, she moved to commercial pursuits which combined science, medicine and health. She is currently Managing Director and Chief Executive Officer of OncoRes Medical, which is developing novel imaging technology to improve cancer outcomes. She is also a Venture Partner at Brandon Capital Partners, a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specialising in seed to earlystage technology investment, and a Founding Director of the Australian Governments National Reconstruction Fund Corporation. She has startup experience in medical apps, diagnostics and fitness devices and has served on the boards of private health care related technology companies. She is a member of the Curtin University Commercialisation Advisory Board
    Mr James Pacey Newcombe Non-Executive Director Nov 2025
    --
    Mr Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
    -
    Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 151,482,588 30.65%
    J P Morgan Nominees Australia Pty Limited 62,585,186 12.66%
    Citicorp Nominees Pty Limited 56,792,007 11.49%
    Jardvan Pty Ltd 15,109,474 3.06%
    Gekramon Investment GmbH & Co. KG 13,802,416 2.79%
    BNP Paribas Noms Pty Ltd 8,357,561 1.69%
    BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> 6,146,467 1.24%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 5,386,200 1.09%
    Argo Investments Limited 4,226,053 0.86%
    National Nominees Limited 3,981,193 0.81%
    Netwealth Investments Limited <Wrap Services A/C> 3,846,986 0.78%
    HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/C> 3,432,756 0.69%
    Australian Foundation Investment Company Limited 3,159,672 0.64%
    Netwealth Investments Limited <Super Services A/C> 1,907,879 0.39%
    Anton-Martin Familienstiftung<Anton-Martin Foundation A/C> 1,864,163 0.38%
    Blaise Mentha 1,850,000 0.37%
    Polly Pty Ltd <A/C Patterson Family> 1,817,416 0.37%
    IOOF Investment Services Limited <IPS Superfund A/C> 1,758,380 0.36%
    Quintal Pty Ltd <Harken Family A/C> 1,587,908 0.32%
    BKI Investment Company Limited 1,462,000 0.29%

    Profile

    since

    Note